Connect with us

Press Release

Manitoba Woman Beats Stage 4 Cancer with Breakthrough CAR T-Cell Therapy

Published

2 years ago

on

–News Direct–

Source: Pexels
Source: Pexels

Disseminated on behalf of CERo Therapeutics Holdings, Inc.

Cancer treatments have come a long way over the years, but there is a newer treatment that is providing even stage four cancer patients with a new lease on life.

The first CAR T-cell therapy was only approved in 2017, but its already having a significant impact in the cancer treatment market. The latest success story comes from Sandra Hajlo, who just became the first person in Manitoba to be declared cancer-free following CAR T-cell therapy.1

Initially diagnosed with stage four B-cell lymphoma in 2015, Hajlo underwent successful chemotherapy. However, eight years later, her cancer returned, leading to another battle with the disease. After a misdiagnosis of scoliosis, a CT scan revealed her cancer had come back.

Her oncologist recommended CAR T-cell therapy, a new treatment where T-cells are modified to target cancer cells, making her the first recipient of this therapy at CancerCare Manitoba.

Dr. David Szwajcer, Manitoba Blood & Marrow Transplant Director at CancerCare Manitoba, explained that the CAR T-cells are collected, sent to a U.S. facility for modification, and then reintroduced to the patient. Hajlo described the procedure as quick and straightforward, taking only 20 minutes.

After undergoing CAR T-cell therapy in December 2023, Hajlo learned in April 2024 that the treatment was successful, and she is cancer-free once again, expressing her gratitude for the second chance at life.

CAR T-cell therapy does not guarantee survival, with about half of the patients not responding,but it has shown promising results in many cases.

CERo Therapeutics Holdings (NASDAQ:CERO) is an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics. CERo Therapeutics is unrelated to CancerCare Manitoba and had no role in the CAR T-cell therapy described above. Nevertheless, CERo Therapeutics believes that the success of the CAR T-cell therapy in Manitoba may provide an indication of the potential for its proprietary CER-T (chimeric engulfment receptor) cell therapy.

CAR-T cell treatment has a steep price tag and some potential serious side effects including secondary cancer developing2 as well as cytokine release syndrome (CRS),3 which causes your immune system to go into overdrive and is potentially life threatening. CER-T cell therapy may provide a more cost-effective alternative with fewer side effects.

CERo Advances Innovative Cancer Immunotherapy

CERo Therapeutics (NASDAQ:CERO) developed CER-T cells to enhance efficiency and reduce side effects compared to traditional therapies by leveraging the body's natural tumor-fighting mechanisms. CER-T cells achieve this through direct tumor killing and by amplifying the body's anti-tumor immune response, and additionally by presenting cancer cell fragments to other immune cells, drawing these cells to attack the tumor.

Peer-reviewed data shows that CER-T cells have at least eight anticancer functions, offering potent, durable, and low-toxicity therapeutic benefits, with the capability to completely eliminate tumors. The company has validated these findings in 10 animal experiments, including a study on Acute Myeloid Leukemia (AML) published in March 2024.

CERo Therapeutics believes CER-T cells offer greater therapeutic potential than currently approved chimeric antigen receptor (CAR-T) cell therapy, potentially targeting both hematological malignancies and solid tumors. The company plans to begin clinical trials for its lead product candidate, CER-1236, in 2024 for treating hematological malignancies.

CERo has been diligently completing pre-clinical studies and documentation necessary to initiate clinical trials after gaining approval from the FDA for its Investigational New Drug (IND) Application.

CERo Therapeutics Holdings, Inc., (NASDAQ:CERO) has successfully completed toxicity studies for CER-1236, a critical step before applying to the FDA for approval to begin human trials. With these studies showing that CER-1236 can be safely administered, the company is now focusing on ensuring safe manufacturing and finalizing its FDA application. Upon FDA acceptance, the company would be able to commence Phase 1 clinical trials, marking the start of the journey toward US approval and addressing unmet medical needs.

CERo plans to update shareholders on their progress, including presentations at investor conferences, potential growth of their intellectual property portfolio, and advancements in other programs beyond AML.

Click here for more information CERo Therapeutics Holdings, Inc., (NASDAQ:CERO).

Footnotes:

[1] https://globalnews.ca/news/10428035/manitobas-first-car-t-cell-therapy-patient-declared-cancer-free/

[2] https://jamanetwork.com/journals/jama/article-abstract/2815500

[3] https://www.pennmedicine.org/cancer/navigating-cancer-care/treatment-types/immunotherapy/what-is-car-t-therapy

Disclosure:

1) The author of the Article, or members of the authors immediate household or family, do not own any securities of the companies outlined in this Article. The author determined which companies would be included in this article based on research and understanding of the sector.

2) The Article was issued on behalf of and sponsored by, CERo Therapeutics Holdings, Inc. Market Jar Media Inc. was paid $1,500 USD for the production and publishing of this article by CERo Therapeutics Holdings, Inc.s Digital Marketing Agency of Record (Native Ads Inc.). Additional details relating to Market Jar Media Inc.s engagement by CERo Therapeutics Holdings, Inc.s Digital Marketing Agency of Record (Native Ads Inc.) are set out in https://pressreach.com/disclaimer-cero.

3) Statements and opinions expressed are the opinions of the author and not Market Jar Media Inc., its directors or officers. The author is wholly responsible for the validity of the statements. The author was not paid by Market Jar Media Inc. for this Article. Market Jar Media Inc. was not paid by the author to publish or syndicate this Article. Market Jar has not independently verified or otherwise investigated all such information. None of Market Jar or any of their respective affiliates, guarantee the accuracy or completeness of any such information. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security. Market Jar Media Inc. requires contributing authors to disclose any shareholdings in, or economic relationships with, companies that they write about. Market Jar Media Inc. relies upon the authors to accurately provide this information and Market Jar Media Inc. has no means of verifying its accuracy.

4) The Article does not constitute investment advice. All investments carry risk and each reader is encouraged to consult with his or her individual financial professional. Any action a reader takes as a result of the information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Market Jar Media Inc.'s terms of use and full legal disclaimer as set forth here. This Article is not a solicitation for investment. Market Jar Media Inc. does not render general or specific investment advice and the information on PressReach.com should not be considered a recommendation to buy or sell any security. Market Jar Media Inc. does not endorse or recommend the business, products, services or securities of any company mentioned on PressReach.com.

5) Market Jar Media Inc. and its respective directors, officers and employees hold no shares for any company mentioned in the Article.

6) This communication contains statements that are forward-looking and as such are not historical facts. This includes, without limitation, statements regarding the financial position, business strategy and the plans and objectives of management for future operations of CERo. These statements constitute projections, forecasts and forward-looking statements, and are not guarantees of performance. Such statements can be identified by the fact that they do not relate strictly to historical or current facts. When used in this communication, words such as anticipate, believe, continue, could, estimate, expect, intend, may, might, plan, possible, potential, predict, project, should, strive, would and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. When CERo discusses its strategies or plans, it is making projections, forecasts or forward-looking statements. Such statements are based on the beliefs of, as well as assumptions made by and information currently available to, CERos management. Actual results could differ from those implied by the forward-looking statements in this communication. Certain risks that could cause actual results to differ are set forth in CERos filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K, filed on April 2, 2024, and the documents incorporated by reference therein. The risks described in CERos filings with the Securities and Exchange Commission are not exhaustive. New risk factors emerge from time to time and it is not possible to predict all such risk factors, nor can CERo assess the impact of all such risk factors on its business, or the extent to which any factor or combination of factors may cause actual results to differ materially from those contained in any forward-looking statements. Forward-looking statements are not guarantees of performance. You should not put undue reliance on these statements, which speak only as of the date hereof. All forward-looking statements made by CERo or persons acting on its behalf are expressly qualified in their entirety by the foregoing cautionary statements. CERo undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

7) Any graphs, tables or other information demonstrating the historical performance or current or historical attributes of CERo Therapeutics Holdings, Inc. or any other entity contained in this document are intended only to illustrate historical performance or current or historical attributes of CERo Therapeutics Holdings, Inc. or such entities and are not necessarily indicative of future performance of CERo Therapeutics Holdings, Inc. or such entities.

8) Investing is risky. The information provided in this article should not be considered as a substitute for professional financial consultation. Users should be aware that investing in any form carries inherent risks, and as such, there is a possibility of losing some or all of their investment. The value of investments can fluctuate significantly within a short period, and investors must understand that past performance is not indicative of future results. Additionally, users should exercise caution as transactions involving investments may be irreversible, even in cases of fraud or accidental actions. It is crucial to acknowledge that rapidly evolving laws and technical issues can have adverse effects on the usability, transferability, exchangeability, and value of investments. Furthermore, users must be cognizant of potential security risks associated with their investment activities. Individuals are strongly encouraged to conduct thorough research, seek professional advice, and carefully evaluate their risk tolerance before engaging in any investment endeavors. Market Jar Media Inc. is neither an investment adviser nor a broker-dealer. The information presented on the website is provided for informative purposes only and is not to be treated as a recommendation to make any specific investment. No such information on PressReach.com constitutes advice or a recommendation.

Contact Details

James Young

+1 800-340-9767

campaigns@pressreach.com

Company Website

https://pressreach.com

View source version on newsdirect.com: https://newsdirect.com/news/manitoba-woman-beats-stage-4-cancer-with-breakthrough-car-t-cell-therapy-472550199

MarketJar

comtex tracking

COMTEX_453434643/2655/2024-06-06T08:32:55

About Author

Cloud PR Wire

See author's posts

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Related Topics:
Continue Reading

Press Release

Malaysia’s AI Future Takes Centre Stage as World AI Show Returns for Its 48th Global Edition

Published

56 minutes ago

on

August 13, 2026

By

Kuala Lumpur, 13 August 2026, ZEX PR WIRE — Artificial intelligence has moved beyond being an emerging technology to become a defining pillar of Malaysia’s economic and digital ambitions. As the country accelerates investments in AI infrastructure, sovereign cloud capabilities, and enterprise-wide transformation, the focus has shifted from experimentation to execution. Against this backdrop, World AI Show Malaysia returns for its 48th Global Edition on 9–10 September 2026 at DoubleTree by Hilton Kuala Lumpur, Malaysia, convening the policymakers, enterprise leaders, technology pioneers, investors, and innovators who are shaping the country’s next chapter of AI-led growth. 

Presented by Trescon, World AI Show Malaysia carries this year’s tagline, “Where Malaysia’s AI Decisions Get Made.” As the country transitions into a strategic AI hub for Southeast Asia and organisations across both the public and private sectors define their AI roadmaps, modernise digital infrastructure, and establish governance frameworks for responsible innovation, the event will provide an executive platform dedicated to meaningful dialogue, strategic partnerships, and commercially relevant outcomes. 

The programme has been curated to address the opportunities and complexities surrounding enterprise AI adoption, sovereign cloud, intelligent infrastructure, cybersecurity, data governance, and responsible AI implementation. Over two days, attendees will engage through keynote addresses, executive panel discussions, fireside conversations, invitation-only boardroom sessions, technology showcases, curated networking engagements, and business meetings designed to facilitate knowledge exchange and cross-sector collaboration. 

The conference will feature an impressive line-up of distinguished government and industry leaders, including: 

  • Budiman Bujang, Deputy Chief Digital Officer, Johor Corporation 

  • Ts. D. Jackson Raao, Principal Assistant Secretary, Ministry of Science, Technology and Innovation (MOSTI) 

  • Jamie Tan, Managing Director, JLL Malaysia 

  • Ganeshbabu Nagarajan, Executive Director – Transformation Programmes, Standard Chartered Bank 

  • Chua Yong Howe, Chief Digital Officer, UEM Edgenta Berhad 

  • Shahrin Oli Mohamed, Group Chief Technology Officer, Pos Malaysia Berhad 

  • Keeratpal Singh, Chief AI and Data Officer (APAC Financial Services), Worldline 

  • Dr. Sadesh Manikam, Executive Vice President, Enterprise Data Office & Data Protection Officer, Bursa Malaysia 

  • Ts. Zairil Anuar Ahmad, Chief Technology Officer, Co-opbank Pertama 

  • Ahmad Faiz, Head – Data & AI, Global Technology Unit, BASF 

  • Raunak Mehta, Chief Executive Officer, Igloo 

  • Muhammad Najib Masdan, Senior Vice President, Khazanah Nasional Berhad 

  • Ts. Narayanan Chidambaram, Head Project Engineering Pod (Technology & Digital PE&T – Digital Project Management) PETRONAS 

  • Mohamed Aafrin, Director of Engineering, DKSH 

  • Sudeep Srivastava, Head – KL IT Center SLB (Schlumberger)  

  • Hong H. Ong, Director of Digital Technology, Labuan Financial Services Authority 

  • Mohd Hanapi Bisri, Senior Digital Industry Leader- Oil & Gas 

  • Dario Bianchi, Chief Product Officer, Mindvalley 

  • G Saravanan, Chief Information Officer, National Cancer Society Malaysia 

 

Reflecting on Malaysia’s AI trajectory, Ts. D. Jackson Raao, Principal Assistant Secretary, MOSTI, said: 

“Malaysia is at a pivotal stage where artificial intelligence is becoming a key driver of national transformation. As we accelerate AI adoption across industries, our focus must remain on responsible innovation, robust governance, strong cybersecurity, and developing a future-ready talent ecosystem. By doing so, Malaysia is well-positioned to emerge as a trusted regional leader in safe and sustainable AI innovation.”

An ecosystem of public sector and technology organisations is supporting this year’s edition. CyberSecurity Malaysia joins as the Supporting Partner, reinforcing the importance of building a secure and trusted digital ecosystem. 

Datadog joins as the Lead Sponsor, Magure as the Platinum Sponsor, Bitdeer AI as the Gold Sponsor, and Alibaba Cloud and Unison Consulting Sdn Bhd as Bronze Sponsors. The exclusive CXO Boardroom sessions will be powered by Zoom and Datadog, while CloudSpace will participate as an exhibitor, showcasing cloud and AI capabilities to enterprise decision-makers. 

Designed exclusively for senior executives, government representatives, and technology leaders, World AI Show Malaysia 2026 will provide a platform where strategic priorities are translated into actionable partnerships, investment opportunities, and real-world AI deployments. As Malaysia continues to strengthen its position within the regional AI landscape, the summit is set to become a key meeting point for organisations shaping the future of intelligent enterprise across Southeast Asia. 

CLAIM YOUR DELEGATE PASS:  Click here

For sponsorship opportunities, speaking engagements, or attendance information, please contact: 

Shrikanth Prabhu
Commercial Director 
Email: prabhu@tresconglobal.com 
Mobile: +91 8660115892

Media Contact: 
Reeha Haris 
Media & PR Executive
Email: reeha@tresconglobal.com 
Mobile: +91 8848655312 

About Author

Cloud PR Wire

See author's posts

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

Phomemo Expands Tattoo Stencil Printer Solutions to Support Professional Artists Evolving Workflows

Published

1 hour ago

on

August 13, 2026

By

New York, New York, United States, 13th Aug 2026 – Phomemo, a global creative printing brand specializing in thermal printing solutions, has expanded its tattoo stencil printer lineup with two new solutions — the Phomemo TA81 Large-Format Tattoo Stencil Printer and Phomemo L85 Smart Touchscreen Tattoo Stencil Printer — designed to support the evolving needs of professional tattoo artists.

From large-scale body art preparation to everyday studio workflows, different tattoo projects require different printing solutions. While some artists prioritize portability and flexibility, others need tools that can handle full-length designs, customized layouts, and more efficient preparation processes.

Alongside established models including the M08F-WS and M08F Plus, Phomemo’s expanded tattoo printer lineup provides artists with multiple options based on their creative style, workflow, and studio needs.

Choosing the Right Tattoo Stencil Printer Matters

For tattoo artists, stencil preparation is an important step between digital design and the final artwork on skin. A reliable tattoo stencil printer can help artists maintain design accuracy, reduce preparation time, and create a smoother workflow before each session.

However, different tattoo styles create different challenges.

Artists specializing in fine details may prioritize clear and portable printing solutions, while those creating sleeves, back pieces, or large-scale compositions often face a different challenge: preparing oversized stencils without manually assembling multiple sections.

Phomemo’s tattoo stencil printer solutions are designed around these different creative scenarios.

Phomemo TA81: A Large-Format Tattoo Stencil Printer Built for Complex Designs

For artists who regularly create full sleeves, back pieces, legs, or other large-scale tattoo projects, stencil preparation can become one of the most time-consuming parts of the workflow.

Traditionally, oversized tattoo designs often require artists to print multiple stencil sheets, trim edges, align different sections, and carefully transfer the assembled design onto the skin. While this approach can work, maintaining accuracy across a large composition can add extra preparation steps and increase the risk of misalignment.

The Phomemo TA81 was designed to address this challenge with continuous, variable-length stencil printing.

Unlike standard sheet-based printing methods, the TA81 uses a roll-fed system that allows artists to print large tattoo designs in one continuous piece. For full sleeves, back pieces, spine designs, or other extended compositions, artists can create a complete stencil without manually cutting and joining multiple sections.

This one-piece printing workflow helps maintain design continuity and makes stencil preparation more efficient for complex tattoo projects.

Beyond size capability, the TA81 focuses on reducing waste during professional workflows. Its variable-length printing system allows artists to print only the required length for each design rather than relying on fixed-size sheets. For busy studios handling multiple projects, this can help optimize transfer paper usage during daily operations.

The TA81 also features Phomemo’s wrinkle-resistant printing technology, designed to help keep transfer paper flat during longer printing processes. Combined with an upgraded print head and edge-stabilizing design, the printer helps deliver consistent and clear stencil lines throughout the entire design.

With Bluetooth and USB connectivity support, the TA81 can connect with smartphones, tablets, laptops, and desktops across Android, iOS, Windows, macOS, and ChromeOS systems, giving artists flexibility when preparing designs.

Through the Phomemo App, artists can adjust designs, preview tattoo layouts, split large images, manage transfer settings, and prepare files before printing.

Phomemo L85: Smart Touchscreen Control for a More Customized Workflow

While large-scale artists may prioritize printing size and efficiency, other tattoo professionals look for a more interactive and customizable stencil preparation experience.

The Phomemo L85 is designed for artists who prefer a smarter workflow with direct control through an integrated touchscreen.

Featuring a 5-inch touchscreen with six language options, the L85 allows artists to manage printing tasks directly from the device. Functions such as template selection, brightness adjustment, print mileage tracking, battery information display, timer settings, sensor calibration, and self-testing can be accessed without relying entirely on another device.

For artists working with different tattoo styles and design formats, flexibility is also important. The L85 supports multiple print sizes, including Letter, A4, B5, A5, and additional width options, allowing artists to prepare different stencil layouts based on their projects.

The L85 also works with the Phomemo App ecosystem, providing creative and editing tools such as image transformation, tattoo extraction, line-art conversion, tattoo preview, and large-image splitting.

Optional AI-assisted features, including AI image generation and tattoo extraction, are designed to support artists during the preparation stage by helping explore ideas, refine concepts, and improve workflow efficiency — while keeping the artist’s own creativity and craftsmanship at the center of the design process.

Portable Tattoo Stencil Solutions: M08F-WS and M08F Plus

For artists who prioritize mobility, Phomemo also offers portable tattoo stencil printer solutions designed for flexible everyday workflows.

The Phomemo M08F-WS provides a lightweight wireless printing solution for artists who need a compact setup. Supporting Bluetooth connectivity and multiple operating systems, it allows artists to prepare tattoo stencils from smartphones, tablets, laptops, and desktops.

The Phomemo M08F Plus builds on this portable concept with a smarter touchscreen experience. Its built-in touchscreen supports functions including brightness adjustment, auto shutdown, calibration, and self-test printing, helping artists complete basic operations directly from the printer.

With thermal printing technology, both models eliminate the need for ink cartridges while providing a convenient solution for tattoo stencil preparation. Through the Phomemo App, artists can access editing tools, stencil generation, previews, and other workflow features designed to simplify the transition from digital artwork to physical stencil.

Choosing the Right Phomemo Tattoo Stencil Printer

Every tattoo artist has a different creative workflow, and the ideal tattoo stencil printer depends on the type of work being created. All can be found on Phomemo’s official site.

Artists working on large-scale compositions such as sleeves and back pieces may benefit from the Phomemo TA81’s continuous full-length printing capability.

Artists looking for a smart, customizable printing experience can explore the Phomemo L85 with touchscreen control and flexible print options.

Artists who need a portable solution for everyday stencil preparation can choose between the lightweight M08F-WS and the upgraded M08F Plus.

By developing tattoo stencil printers for different artistic scenarios, Phomemo continues to help tattoo professionals simplify preparation, improve efficiency, and focus more on the creative process.

About Phomemo

Phomemo is a global creative printing brand dedicated to making everyday printing simple, enjoyable, and accessible. Backed by over 12 years of expertise in thermal printing technology and trusted by over 40 million users worldwide, Phomemo continues to develop the evolution of smart printing. From home organization to global e-commerce, Phomemo lowers the barrier to professional results, enabling ideas and commerce to flow freely.

Media Contact

Organization: Phomemo

Contact Person: Alicia Chen

Website: https://phomemo.com

Email:
influencerscenter@phomemo.com

City: New York

State: New York

Country:United States

Release id:48084

The post Phomemo Expands Tattoo Stencil Printer Solutions to Support Professional Artists Evolving Workflows appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section

file

About Author

Cloud PR Wire

See author's posts

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

SBCFX to Showcase Trading Innovation, Regional Growth Strategy, and Future Vision at iFX EXPO Asia 2026

Published

2 hours ago

on

August 13, 2026

By

Hong Kong, Hong Kong, August 13th, 2026, FinanceWire

SBCFX has announced its participation in iFX EXPO Asia 2026, one of the leading B2B exhibitions for the online trading, fintech, and financial services sectors. 

Scheduled to take place on 8–9 October 2026 at the Hong Kong Convention and Exhibition Centre (HKCEC), the event is expected to attract a diverse range of industry stakeholders, including brokers, traders, investors, Introducing Brokers (IBs), affiliates, fintech companies, liquidity providers, and financial services professionals from across Asia and beyond. 

As part of its ongoing international expansion strategy, SBCFX will showcase its integrated trading ecosystem, including the MetaTrader 5 (MT5) platform, multi-asset CFD trading capabilities, institutional-grade liquidity services, and its latest digital trading solutions. The company will also use the exhibition as a platform to share its growth strategy, technology roadmap, and long-term vision for the evolving global trading landscape. 

“iFX EXPO Asia represents an important opportunity for SBCFX to strengthen its engagement with the Asian trading community and further expand its regional network,” said David, CEO of SBCFX. 

“Our ambition is to become one of the most trusted global trading brands by bridging technology, education, and market access. We believe the future of online trading is not only about faster execution and better tools, but also about creating an ecosystem where traders, partners, and institutions can grow together. iFX EXPO Asia provides the perfect platform for us to share this vision and connect with the industry.” 

Driving Innovation While Building a Sustainable Trading Ecosystem 

Technology and innovation remain central to SBCFX’s long-term development strategy. The company continues to invest in digital infrastructure, trading technology, and client-focused solutions designed to enhance trading efficiency and improve user experience across global markets. 

Alongside its trading services, SBCFX will soon introduce a new mobile trading application that will provide clients with convenient access to account management, market information, trading tools, and platform services through a unified interface. The upcoming launch reflects the company’s ongoing efforts to improve accessibility and streamline the trading experience for users worldwide.   

Looking ahead, SBCFX remains focused on developing innovative solutions that support traders at every stage of their journey while strengthening connections between retail investors, institutional partners, and the broader financial ecosystem. By combining advanced technology with a client-centric approach, the company aims to create a smarter, more connected trading environment that adapts to the evolving needs of modern market participants. 

During the two-day event, SBCFX representatives will engage with prospective clients, Introducing Brokers, institutional partners, and technology providers to explore strategic collaborations and support the company’s continued growth across Asia. 

Meet SBCFX at Booth 37 

SBCFX welcomes individual traders, Introducing Brokers, affiliates, fintech firms, liquidity providers, institutional investors, and technology partners to visit Booth 37 and learn more about the company’s products, services, and strategic development plans. 

Visitors to the booth will have the opportunity to meet members of the SBCFX team, explore the company’s latest initiatives, and receive a selection of exclusive SBCFX promotional gifts and event merchandise available throughout the exhibition while supplies last. 

To facilitate more in-depth discussions and personalised consultations, attendees are encouraged to schedule a one-on-one meeting with the SBCFX team in advance via the following booking link: 

https://forms.cloud.microsoft/r/QwRd66ZmQa 

Event Details 

Event: iFX EXPO Asia 2026 

Date: 8–9 October 2026 

Time: 10:00 AM – 6:00 PM 

Venue: Hong Kong Convention and Exhibition Centre (HKCEC), Hong Kong 

Booth: 37 

For media enquiries or further information, please contact SBCFX at cs@sbcfx.com. 

About SBCFX 

SBCFX is a global financial services provider committed to delivering innovative online trading solutions supported by advanced technology, institutional-grade liquidity, and exceptional client service. Through continuous investment in technology, regulatory compliance, and strategic partnerships, SBCFX provides access to a wide range of global financial markets while empowering traders, Introducing Brokers, affiliates, and institutional partners to achieve long-term success. 

With a vision to become a trusted global brokerage, SBCFX remains dedicated to transparency, innovation, and sustainable growth, delivering world-class trading solutions to clients around the world. 

Contact

Marketing Executive
Kit Cheung
SBCFX
marketing@sbcfx.com

About Author

Cloud PR Wire

See author's posts

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

LATEST POST

Like Us
Follow Us
Subscribe Us
Follow Us